Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN MONOHYDRATE MACROCRYSTALS versus XIFYRM.
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
500 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category D/X
Category C
Antibiotic
Antibiotic